The 2021 AHA/American Stroke Association Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack support the use of GLP-1-R as an addition to metformin in patients with T2DM and established ASCVD in order to reduce stroke risk [9]. Here, GLP1R is linked to atherosclerosis.